EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Neuroprotective strategies for cognitive decline in type 2 diabetes

Flavia A Cimini, Aida Cuenca-Royo, Maria Gomis-Gonzalez, Laura Forcano, Ilaria Barchetta, Eugenio Barone, Maria G Cavallo, Rafael De La Torre

Trends in Endocrinology & Metabolism · 2026-11 · 37 (11) · 1088-1102

DOI: 10.1016/j.tem.2026.04.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2026-11. Verfasst von Flavia A Cimini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cognitive Dysfunction, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) is increasingly associated with cognitive impairment and dementia, reflecting the combined impact of metabolic dysregulation, vascular injury, neuroinflammation, and defective brain insulin signaling. While this link is now well recognized, it remains unclear whether cognitive decline in T2D is modifiable. This review focuses on emerging neuroprotective strategies, highlighting both pharmacological and lifestyle-based interventions. Recent evidence indicates that some glucose-lowering agents, notably metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists, may exert pleiotropic effects on brain metabolism, inflammation, and vascular integrity beyond glycemic control. We propose a conceptual shift in T2D management in which cognitive preservation becomes an explicit therapeutic objective, integrating metabolic control with targeted brain-protective approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cognitive DysfunctionNeuroprotective AgentsHumansHypoglycemic AgentsAnimals

Stichwörter der Autor:innen

brain insulin resistancecognitive impairmentcognitive prevention strategiesmetabolic–cognitive axisneuroprotectiontype 2 diabetes

Substanzen

Neuroprotective AgentsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Integrative Pharmacology and Systems Neurosciences Research Group, Hospital del Mar Research Institute, Barcelona, Spain.
  • Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.
  • Integrative Pharmacology and Systems Neurosciences Research Group, Hospital del Mar Research Institute, Barcelona, Spain; Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Physiopatholog…

Zitieren

APA

Cimini, F. A., Cuenca-Royo, A., Gomis-Gonzalez, M., Forcano, L., Barchetta, I., Barone, E., Cavallo, M. G., & De La Torre, R. (2026). Neuroprotective strategies for cognitive decline in type 2 diabetes. Trends in Endocrinology & Metabolism, 37(11), 1088-1102. https://doi.org/10.1016/j.tem.2026.04.003

Vancouver

Cimini FA, Cuenca-Royo A, Gomis-Gonzalez M, Forcano L, Barchetta I, Barone E, et al. Neuroprotective strategies for cognitive decline in type 2 diabetes. Trends in Endocrinology & Metabolism. 2026;37(11):1088-1102. doi:10.1016/j.tem.2026.04.003

BibTeX
@article{Cimini2026,
  author = {Cimini, Flavia A and Cuenca-Royo, Aida and Gomis-Gonzalez, Maria and Forcano, Laura and Barchetta, Ilaria and Barone, Eugenio and Cavallo, Maria G and De La Torre, Rafael},
  title = {Neuroprotective strategies for cognitive decline in type 2 diabetes},
  journal = {Trends in Endocrinology & Metabolism},
  year = {2026},
  volume = {37},
  number = {11},
  pages = {1088--1102},
  doi = {10.1016/j.tem.2026.04.003}
}
Kostenlos starten →